

CURRICULUM VITAE JEDIDIAH INDIGO MORTON

February 28, 2024

Email: Jedidiah.Morton@monash.edu

Phone: [0403 487 378](tel:0403487378)

Research Fellow

Monash University, Melbourne, Australia.

381 Royal Parade, Parkville, Victoria, Australia, 3052.

Postdoctoral Researcher

Baker Heart and Diabetes Institute, Melbourne, Australia.

75 Commercial Road, Melbourne, Victoria, Australia, 3004.

Contents

Professional appointments	2
Other positions	2
Qualifications	2
Scholarships and awards	2
Competitive grant funding	2
Publications	3

Professional Appointments

2023-	Baker Heart and Diabetes Institute. Postdoctoral researcher.
2022-	Monash University. Research fellow.
2021-2022	Monash University. Teaching associate.
2019-2022	Monash University. Monash University and Baker Heart and Diabetes Institute. PhD candidate.
2018-2019	Monash University. University of Melbourne. Research assistant.

Other positions

2023-	International Diabetes Federation, Diabetes Atlas Economic Impact of Diabetes Special Interest Group. Member.
2023-	Victorian Government, Department of Health, Safer Care Victoria Cardiovascular Learning Health Network Data Group. Member.
2022-	GLOBODIAB study. Principal analyst.
2022	Baker Heart and Diabetes Institute. Honorary appointment.

Qualifications

2018	Bachelor of Science (Honours), University of Melbourne.
2022	Doctor of Philosophy, Monash University.

Scholarships and Awards

2022	Finalist – Victorian Premier’s Awards for Health and Medical Research, Department of Health, Victorian Government.
2022	Damien Jolly Award for Higher Degree by Research Thesis Excellence, Monash University.
2022	Baker research prize for publication excellence, Baker Heart and Diabetes Institute.
2021	Finalist – Baker best publication award, Baker Heart and Diabetes Institute.
2021	Baker research prize for publication excellence, Baker Heart and Diabetes Institute.
2021	School of Public Health and Preventive Medicine best HDR paper award, Monash University.
2020	Finalist – Baker best publication award, Baker Heart and Diabetes Institute
2019-2022	Monash Graduate Excellence Scholarship, Monash University.
2019-2022	Australian Government Research Training Program Scholarship, Monash University.
2018	John A. McKenzie / Selby Scientific Foundation Award, University of Melbourne.
2017	Howitt Natural History Scholarship, University of Melbourne.
2016-2017	Dean’s Honours List, University of Melbourne.

Competitive grant funding

2023	45 and Up Cardiovascular Research Grant, The Heart Foundation. \$120,000.
------	---

Publications

- [1] George SQ Tan, Jedidiah I Morton, Stephen Wood, Natalie L Trevaskis, Dianna J Magliano, John Windsor, Jonathan E Shaw, and Jenni Ilomäki. Cox2 inhibitor use and type 2 diabetes treatment intensification: A registry-based cohort study. *Diabetes Research and Clinical Practice*, 207:111082, 2024.
- [2] Adam C Livori, Zanfina Ademi, Jenni Ilomäki, Derk Pol, Jedidiah I Morton, and J Simon Bell. No effect of remoteness on clinical outcomes following myocardial infarction: An analysis of 43,729 myocardial infarctions in victoria, australia. *International Journal of Cardiology*, 398:131593, 2024.
- [3] Adam C Livori, Zanfina Ademi, Jenni Ilomäki, Derk Pol, Jedidiah I Morton, and J Simon Bell. Use of secondary prevention medications in metropolitan and non-metropolitan areas: an analysis of 41 925 myocardial infarctions in australia. *European Journal of Preventive Cardiology*, page zwad360, 2023.
- [4] Clara Marquina, Jedidiah I Morton, and Zanfina Ademi. Health economics of detection and treatment of children with familial hypercholesterolemia: To screen or not to screen is no longer the question. *Current Opinion in Endocrinology, Diabetes and Obesity*, pages 10–1097, 2023.
- [5] Berhanu Elfu Feleke, Jedidiah Morton, Dianna Magliano, and Jonathan E Shaw. Trends of hospitalisation for cardiovascular diseases among people with diabetes in australia. *Diabetes Research and Clinical Practice*, 205:110973, 2023.
- [6] Louise Lord, Mark Hew, Miriam TY. Leung, Jedidiah I. Morton, and Jenni Ilomäki. Medication use in people with cystic fibrosis before and after modulator therapy. *Pulmonary Pharmacology & Therapeutics*, 83:102264, 2023.
- [7] Tamrat Befekadu Abebe, Jedidiah I Morton, Jenni Ilomäki, and Zanfina Ademi. Future burden of myocardial infarction in australia: impact on health outcomes between 2019 and 2038. *European Heart Journal-Quality of Care and Clinical Outcomes*, page qcad062, 2023.
- [8] Jedidiah I Morton, Clara Marquina, Melanie Lloyd, Gerald F Watts, Sophia Zoungas, Danny Liew, and Zanfina Ademi. Lipid-lowering strategies for primary prevention of coronary heart disease in the uk: a cost-effectiveness analysis. *PharmacoEconomics*, pages 1–17, 2023.
- [9] Jedidiah I Morton, Bendix Carstensen, Stephen P McDonald, Kevan R Polkinghorne, Jonathan E Shaw, and Dianna J Magliano. Trends in the incidence of end-stage kidney disease in type 1 and type 2 diabetes in australia, 2010-2019. *American Journal of Kidney Diseases*, 82(5):608–616, 2023.
- [10] Hannah Doody, Adam Livori, Justine Ayre, Zanfina Ademi, J Simon Bell, and Jedidiah I Morton. Guideline concordant prescribing following myocardial infarction in people who are frail: a systematic review. *Archives of Gerontology and Geriatrics*, page 105106, 2023.

- [11] Clara Marquina, Jedidiah Morton, Tom Brett, Melanie Lloyd, Jan Radford, Clare Heal, Charlotte Hespe, Gerard Gill, David Sullivan, Ella Zomer, et al. Enhancing the detection and care of heterozygous familial hypercholesterolemia in primary care: Cost-effectiveness and return on investment. *Circulation: Genomic and Precision Medicine*, page e003842, 2023.
- [12] Dina Abushanab, Clara Marquina, Jedidiah I Morton, Daoud Al-Badriyeh, Melanie Lloyd, Dianna J Magliano, Danny Liew, and Zanfina Ademi. Projecting the health and economic burden of cardiovascular disease among people with type 2 diabetes, 2022–2031. *PharmacoEconomics*, 41(6):719–732, 2023.
- [13] Melanie Lloyd, Jedidiah Morton, Helena Teede, Clara Marquina, Dina Abushanab, Dianna J Magliano, Emily J Callander, and Zanfina Ademi. Long-term cost-effectiveness of implementing a lifestyle intervention during pregnancy to reduce the incidence of gestational diabetes and type 2 diabetes. *Diabetologia*, 66(7):1223–1234, 2023.
- [14] Jedidiah I Morton, Clara Marquina, Dianna J Magliano, Jonathan E Shaw, and Zanfina Ademi. Targeting diabetes prevention to more disadvantaged groups improves cost-effectiveness: Implications of inequality in type 2 diabetes from theoretical interventions. *Value in Health*, 2023.
- [15] Dunya Tomic, Jedidiah I Morton, Agus Salim, Tim Lambert, Dianna J Magliano, and Jonathan E Shaw. Hospitalisation for mental health disorders in australians with type 1 or type 2 diabetes. *Diabetes Research and Clinical Practice*, 196:110244, 2023.
- [16] Peter A Lazzarini, Susanna M Cramb, Jonathan Golledge, Jedidiah I Morton, Dianna J Magliano, and Jaap J Van Netten. Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century. *Diabetologia*, 66(2):267–287, 2023.
- [17] Matthew Quigley, Jedidiah I Morton, Peter A Lazzarini, Sophia Zoungas, Jonathan E Shaw, and Dianna J Magliano. Trends in diabetes-related foot disease hospitalizations and amputations in australia, 2010 to 2019. *Diabetes Research and Clinical Practice*, 194:110189, 2022.
- [18] C Marquina, J Morton, E Zomer, S Talic, S Lybrand, D Thomson, D Liew, and Z Ademi. Lost therapeutic benefit of delayed ldl-c control in statin treated patients and cost-effectiveness analysis of lipid-lowering intensification. *Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research*, pages S1098–3015, 2022.
- [19] Jedidiah I Morton, Clara Marquina, Jonathan E Shaw, Danny Liew, Kevan R Polkinghorne, Zanfina Ademi, and Dianna J Magliano. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread sglt2i and glp-1 ra use: a cost-effectiveness analysis. *Diabetologia*, 66(4):642–656, 2023.
- [20] Dunya Tomic, Agus Salim, Jedidiah I Morton, Dianna J Magliano, and Jonathan E Shaw. Reasons for hospitalisation in australians with type 2 diabetes compared to the general population, 2010–2017. *Diabetes Research and Clinical Practice*, 194:110143, 2022.
- [21] Dunya Tomic, Jedidiah I Morton, Lei Chen, Agus Salim, Edward W Gregg, Meda E Pavkov, Martti Arffman, Ran Balicer, Marta Baviera, Elise Boersma-van Dam, et al. Lifetime risk,

- life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study. *The Lancet Diabetes & Endocrinology*, 10(11):795–803, 2022.
- [22] Jedidiah I Morton, Danny Liew, Stephen J Nicholls, and Zanfina Ademi. Should we continue to subsidise therapeutics with uncertain efficacy? health economic implications for icosapent ethyl. *European Journal of Preventive Cardiology*, 30(17):1935–1938, 2023.
 - [23] Zanfina Ademi, Jedidiah I Morton, Danny Liew, Stephen J Nicholls, Sophia Zoungas, and Brian A Ference. Integrating the biology of cardiovascular disease into the epidemiology of economic decision modelling via mendelian randomisation. *Pharmacoeconomics*, 40(11):1033–1042, 2022.
 - [24] Jedidiah I Morton, Peter A Lazzarini, Kevan R Polkinghorne, Bendix Carstensen, Dianna J Magliano, and Jonathan E Shaw. The association of attained age, age at diagnosis, and duration of type 2 diabetes with the long-term risk for major diabetes-related complications. *Diabetes Research and Clinical Practice*, 190:110022, 2022.
 - [25] Jedidiah I Morton, Jenni Ilomäki, Dianna J Magliano, and Jonathan E Shaw. Persistent disparities in diabetes medication receipt by socio-economic disadvantage in australia. *Diabetic Medicine*, 39(9):e14898, 2022.
 - [26] Jedidiah I Morton, Jenni Ilomäki, Stephen J Wood, J Simon Bell, Quan Huynh, Dianna J Magliano, and Jonathan E Shaw. Treatment gaps, 1-year readmission and mortality following myocardial infarction by diabetes status, sex and socioeconomic disadvantage. *J Epidemiol Community Health*, 76(7):637–645, 2022.
 - [27] Oyunchimeg Buyadaa, Agus Salim, Jedidiah I Morton, Karin Jandeleit-Dahm, Dianna J Magliano, and Jonathan E Shaw. Examining the factors contributing to the association between non-albuminuric ckd and a low rate of kidney function decline in diabetes. *Therapeutic Advances in Endocrinology and Metabolism*, 13:20420188221083518, 2022.
 - [28] Paz LD Ruiz, Lei Chen, Jedidiah I Morton, Agus Salim, Bendix Carstensen, Edward W Gregg, Meda E Pavkov, Manel Mata-Cases, Didac Mauricio, Gregory A Nichols, et al. Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts. *Diabetologia*, 65(6):964–972, 2022.
 - [29] Jedidiah I Morton, Peter A Lazzarini, Jonathan E Shaw, and Dianna J Magliano. Trends in the incidence of hospitalization for major diabetes-related complications in people with type 1 and type 2 diabetes in australia, 2010–2019. *Diabetes care*, 45(4):789–797, 2022.
 - [30] Jedidiah I Morton, Jenni Ilomäki, Stephen J Wood, J Simon Bell, Jonathan E Shaw, and Dianna J Magliano. One-year readmission and mortality following ischaemic stroke by diabetes status, sex, and socioeconomic disadvantage: an analysis of 27,802 strokes from 2012 to 2017. *Journal of the Neurological Sciences*, 434:120149, 2022.
 - [31] Kaitlyn Hastings, Clara Marquina, Jedidiah Morton, Dina Abushanab, Danielle Berkovic, Stella Talic, Ella Zomer, Danny Liew, and Zanfina Ademi. Projected new-onset cardiovascular disease by socioeconomic group in australia. *Pharmacoeconomics*, pages 1–12, 2022.

- [32] Jedidiah I Morton, Julian W Sacre, Stephen P McDonald, Dianna J Magliano, and Jonathan E Shaw. Excess all-cause and cause-specific mortality for people with diabetes and end-stage kidney disease. *Diabetic Medicine*, 39(6):e14775, 2022.
- [33] Jessica L Harding, Jedidiah I Morton, Jonathan E Shaw, Rachel E Patzer, Stephen P McDonald, and Dianna J Magliano. Changes in excess mortality among adults with diabetes-related end-stage kidney disease: a comparison between the usa and australia. *Nephrology Dialysis Transplantation*, 37(10):2004–2013, 2022.
- [34] Oyunchimeg Buyadaa, Agus Salim, Jedidiah I Morton, Dianna J Magliano, and Jonathan E Shaw. Rate of decline in kidney function and known age-of-onset or duration of type 2 diabetes. *Scientific Reports*, 11(1):14705, 2021.
- [35] Jedidiah I Morton, Stephen P McDonald, Agus Salim, Danny Liew, Jonathan E Shaw, and Dianna J Magliano. Projecting the incidence of type 2 diabetes-related end-stage kidney disease until 2040: A comparison between the effects of diabetes prevention and the effects of diabetes treatment. *Diabetes Care*, 44(7):1515–1523, 2021.
- [36] Jedidiah I Morton, Jenni Ilomäki, Dianna J Magliano, and Jonathan E Shaw. The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in australia: a nationwide registry study. *Diabetologia*, 64:349–360, 2021.
- [37] Jedidiah I Morton, Danny Liew, Stephen P McDonald, Jonathan E Shaw, and Dianna J Magliano. The association between age of onset of type 2 diabetes and the long-term risk of end-stage kidney disease: a national registry study. *Diabetes Care*, 43(8):1788–1795, 2020.